Drug intelligence / Profile preview

recombinant human collagen + silver nanoparticles

Development stage
Preclinical
Modality
Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
Administration
Topical
01

Overview

Recombinant human collagen + silver nanoparticles is a **combination wound-healing biomaterial** that pairs bioengineered human collagen with antimicrobial silver nanoparticles, typically for topical use in dressings, gels, hydrogels, films, or wound matrices. The recombinant human collagen component primarily acts as a biocompatible extracellular-matrix scaffold that supports cell adhesion, granulation tissue formation, re-epithelialization, and tissue repair, while the silver nanoparticle component provides broad antimicrobial activity through local silver ion release and microbicidal effects on wound pathogens. Based on the available literature, this term appears to refer to a **product concept or formulation category rather than a single uniquely identified marketed drug**, and published uses are mainly in wound care, burn repair, postoperative healing, and other skin or soft-tissue injury settings.

Other names
recombinant human collagen + silver nanoparticlescollagen-silver compound
02

Targets

NeuraminidaseFtsZ (Filamentous temperature-sensitive protein Z)70S ribosome (Bacterial protein synthesis ribosome complex)

Beyond the preview

Go deeper on recombinant human collagen + silver nanoparticles.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant human collagen + silver nanoparticles.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call